We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Bacteria Engineered to Detect Tumor DNA Could Seek and Destroy Gastrointestinal and Other Cancers

By LabMedica International staff writers
Posted on 11 Aug 2023
Print article
Image: As seen in a dish, Acinetobacter baylyi (green) bacteria surround clumps of colorectal cancer cells (Photo courtesy of UC San Diego)
Image: As seen in a dish, Acinetobacter baylyi (green) bacteria surround clumps of colorectal cancer cells (Photo courtesy of UC San Diego)

Tumors release their DNA into their surrounding environment, a phenomenon known as shedding. While various technologies can analyze purified DNA in laboratory settings, they fall short in detecting DNA in its released state. Although bacteria have been engineered for diverse diagnostic and therapeutic tasks, they cannot recognize specific DNA sequences and mutations outside of cells. Now, researchers have engineered bacteria that can identify tumor DNA in a live organism. This innovation, which successfully detected cancer in the colons of mice, has the potential for the creation of new biosensors to identify infections, cancers, and other diseases.

Under the new “Cellular Assay for Targeted CRISPR-discriminated Horizontal gene transfer,” or “CATCH,” strategy, scientists from the University of California San Diego (La Jolla, CA, USA) used CRISPR technology to engineer bacteria capable of assessing free-floating DNA sequences on a genomic level. These samples were then compared with predetermined cancerous sequences. The concept involved repurposing bacteria that are naturally present in the colon as biosensors, capable of detecting DNA released from colorectal tumors. The focus was on Acinetobacter baylyi, a bacterium in which the essential components for both acquiring DNA and utilizing CRISPR for analysis were identified.

The researchers proceeded to design, construct, and assess Acinetobacter baylyi as a sensor for detecting DNA from the KRAS gene, which is frequently mutated in various cancers. They programmed the bacterium with a CRISPR system to differentiate between mutant and normal (non-mutated) variants of the KRAS gene. Consequently, only bacteria that had incorporated mutant KRAS forms, as present in precancerous growths and cancers, would survive to indicate or respond to the disease. This research builds upon the concept of horizontal gene transfer, a method by which genetic material is exchanged among organisms in a manner distinct from traditional genetic inheritance. While horizontal gene transfer is commonly observed between bacteria, the researchers successfully adapted this concept from mammalian tumors and human cells into bacteria.

The researchers are presently refining their bacteria-based biosensor strategy, exploring new circuits and various bacterial species for detecting and treating human cancers and infections. Researchers believe that in the future, cellular interventions will surpass traditional medicinal approaches. A living bacterium capable of detecting DNA within the gastrointestinal tract holds remarkable potential as a sentinel for identifying and combating gastrointestinal cancers, along with numerous other malignancies.

“There is so much potential to engineer bacteria to prevent colorectal cancer, a tumor that is immersed in a stream of bacteria, that could help, or hinder, its progression,” said researcher Susan Woods.

Related Links:
UC San Diego

New
Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Magnetic Bead Separation Modules
MAG and HEATMAG

Print article
77 ELEKTRONIKA

Channels

Clinical Chemistry

view channel
Image: PhD student and first author Tarek Eissa has analyzed thousands of molecular fingerprints (Photo courtesy of Thorsten Naeser / MPQ / Attoworld)

Screening Tool Detects Multiple Health Conditions from Single Blood Drop

Infrared spectroscopy, a method using infrared light to study the molecular composition of substances, has been a foundational tool in chemistry for decades, functioning similarly to a molecular fingerprinting... Read more

Hematology

view channel
Image: The Truvian diagnostic platform combines clinical chemistry, immunoassay and hematology testing in a single run (Photo courtesy of Truvian Health)

Automated Benchtop System to Bring Blood Testing To Anyone, Anywhere

Almost all medical decisions are dependent upon laboratory test results, which are essential for disease prevention and the management of chronic illnesses. However, routine blood testing remains limited worldwide.... Read more

Immunology

view channel
Image: The blood test measures lymphocytes  to guide the use of multiple myeloma immunotherapy (Photo courtesy of 123RF)

Simple Blood Test Identifies Multiple Myeloma Patients Likely to Benefit from CAR-T Immunotherapy

Multiple myeloma, a type of blood cancer originating from plasma cells in the bone marrow, sees almost all patients experiencing a relapse at some stage. This means that the cancer returns even after initially... Read more

Microbiology

view channel
Image: Ultra-Rapid Antimicrobial Susceptibility Testing (uRAST) revolutionizing traditional antibiotic susceptibility testing (Photo courtesy of Seoul National University)

Ultra-Rapid Culture-Free Sepsis Test Reduces Testing Time from Days to Hours

Sepsis, a critical emergency condition, results from an overactive inflammatory response to pathogens like bacteria or fungi in the blood, leading to organ damage and the possibility of sudden death.... Read more

Pathology

view channel
Image: The AI model can distinguish different stages of DCIS from inexpensive and readily available breast tissue images (Photo courtesy of David A. Litman/Shutterstock)

AI Model Identifies Breast Tumor Stages Likely To Progress to Invasive Cancer

Ductal carcinoma in situ (DCIS) is a non-invasive type of tumor that can sometimes progress to a more lethal form of breast cancer and represents about 25% of all breast cancer cases. Between 30% and 50%... Read more

Industry

view channel
Image: Beckman Coulter will utilize the ALZpath pTau217 antibody to detect key biomarker for Alzheimer\'s disease on its DxI 9000 immunoassay analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter Licenses Alzpath's Proprietary P-tau 217 Antibody to Develop Alzheimer's Blood Test

Cognitive assessments have traditionally been the primary method for diagnosing Alzheimer’s disease, but this approach has its limitations as symptoms become apparent only after significant brain changes... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.